ARSL

Across TCGA pan-cancer cohorts, ARSL mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ARSL’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where ARSL mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ARSL is over-expressed in tumor, although a few such as PDAC and LUAD show the opposite, repressed pattern.

PDAC, LUAD, and COAD are the cancer types where ARSL tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARSL mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Male	All	−1.510	<.001	6	view →
LUAD	Male	III,IV	−0.555	<.001	6	view →
COAD	Female	All	+0.226	.018	3	view →
LSCC	All	All	−0.377	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ARSL–PDAC

Open the PDAC breakdown →